Whether Elacetrant has been included in the medical insurance catalog and interpretation of relevant policies on medical insurance reimbursement

Elacestrant (Elacestrant) is an oral estrogen receptor degrader (SERD), mainly used to treat hormone receptor-positive, HER2-negative metastatic breast cancer. As of now, the drug has not yet been launched in China, so domestic patients cannot purchase it directly through hospital pharmacies or formal channels. There is still no pricing and circulation information in the domestic market, and patients need to pay attention to drug launch dynamics and clinical accessibility.

Since elastran has not yet been marketed in the country, it has not yet been included in the national medical insurance directory. This means that even if a drug is launched in the future, it will still need to go through medical insurance review and price negotiation to determine the scope of reimbursement. If patients need to use the drug, they can only pay for it at their own expense or obtain it through formal overseas channels. Currently, they are not eligible for domestic medical insurance reimbursement policies.

In overseas markets, the price of the original drug ilastrast is relatively high, with the European version costing about more than 30,000 yuan per box. In contrast, there are already generic drugs in the Laos market, the price is about more than 2,000 yuan, and the ingredients of the drugs are basically the same as the original drugs. When patients choose to purchase drugs overseas, they should ensure the quality and legality of the drugs through formal channels, and consider transportation and customs clearance risks.

For domestic patients who are not covered by medical insurance, they can pay attention to the International Patient Assistance Program (PAP) or clinical trial projects, which may provide discounts or free drug support. When using elastran, individual dosage adjustment should be made under the guidance of a professional doctor, and blood routine, liver function and cardiovascular indicators should be monitored regularly to ensure efficacy and safety. Reasonable planning of medication and financial arrangements can help patients obtain the best treatment results within their affordability.

Reference materials:https://www.drugs.com/